When Liver Disease Isn’t Viral
Not every liver condition stems from infection. The immune system can mistakenly attack the liver directly, tumours can develop silently over years, and the pancreas, working closely alongside the liver in digestion, can develop its own distinct problems requiring specialised investigation beyond standard liver testing.
This guide covers that specialist panel at Altus Lab. If you’re earlier in your investigation, screening for viral hepatitis or evaluating basic liver function, read our companion guide to viral hepatitis and liver function tests covering that starting panel.
Every test here is supervised by Dr. Alok Gupta, MD Pathology, Ex-PGIMER Chandigarh, with home sample collection available across Chandigarh, Mohali, and Panchkula.
Autoimmune Hepatitis Profile (ANA, ASMA, LKM-1, SLA)
This comprehensive panel tests for four distinct autoantibodies associated with Autoimmune Hepatitis, a condition where the immune system mistakenly attacks liver cells directly, causing inflammation and progressive damage if left untreated, yet responding well to immunosuppressive treatment once correctly identified.
Testing multiple antibodies together matters significantly, since different patterns help classify Autoimmune Hepatitis into distinct subtypes, information that can influence treatment approach and prognosis. Some patients show a classic pattern, while others present with more unusual combinations requiring careful clinical interpretation.
At Altus Lab, we recommend this comprehensive panel whenever unexplained elevated liver enzymes occur alongside negative viral hepatitis screening, particularly in younger patients or those with other autoimmune conditions, since Autoimmune Hepatitis often responds dramatically well to treatment once correctly diagnosed.
Anti-Mitochondrial Antibody (AMA)
Anti-Mitochondrial Antibody testing serves as the primary diagnostic marker for Primary Biliary Cholangitis, a chronic autoimmune condition affecting the small bile ducts within the liver, causing progressive damage that, left untreated, can eventually lead to significant liver scarring and dysfunction over time.
This test shows remarkably high specificity for this condition, meaning a positive result strongly supports the diagnosis when combined with appropriate clinical findings, including elevated ALP and GGT, and typical symptoms like fatigue and itching that often develop gradually over months or years.
At Altus Lab, we recommend AMA testing for patients with unexplained elevated ALP alongside fatigue or itching, particularly in middle-aged women, who represent the population most commonly affected by this condition, since early diagnosis allows treatment that can meaningfully slow disease progression.
Alpha-Fetoprotein (AFP)
AFP serves as an important tumour marker for hepatocellular carcinoma, the most common form of primary liver cancer, making regular monitoring particularly valuable for patients with chronic liver disease, cirrhosis, or chronic viral hepatitis, all conditions that significantly increase liver cancer risk over time.
While elevated AFP doesn’t automatically confirm cancer, since levels can rise during pregnancy and in certain benign liver conditions too, persistently rising levels in a patient with known liver disease warrant prompt further investigation, typically including imaging to look for concerning findings.
At Altus Lab, we recommend regular AFP monitoring, typically every six months, for patients with cirrhosis or chronic hepatitis as part of standard liver cancer surveillance, since catching liver cancer at an early, more treatable stage significantly improves long-term outcomes for patients.
PIVKA-II (Des-Gamma-Carboxyprothrombin)
PIVKA-II represents a complementary tumour marker for hepatocellular carcinoma, working through a different biological mechanism than AFP, which means some liver cancers that don’t produce elevated AFP will still show elevated PIVKA-II, and vice versa, making combined testing more sensitive than either marker alone.
This complementary relationship matters clinically, since relying on AFP alone can occasionally miss cases where liver cancer doesn’t significantly elevate this particular marker. Testing both together improves the overall detection rate during cancer surveillance programs for at-risk liver disease patients.
At Altus Lab, we recommend PIVKA-II testing alongside AFP for comprehensive liver cancer surveillance in high-risk patients, since this combined approach provides meaningfully better sensitivity than AFP testing alone, helping catch cases that might otherwise be missed during routine monitoring.
CEA
CEA, while more commonly associated with colorectal cancer, also has relevance in certain liver and biliary conditions, sometimes tested alongside other tumour markers when investigating unclear liver masses or when distinguishing between different potential cancer origins affecting the liver or bile ducts.
This marker works best as part of a broader diagnostic picture rather than a standalone answer, since elevation can occur across several different cancer types and even some non-cancerous conditions, requiring careful clinical interpretation alongside imaging and other test results.
At Altus Lab, we include CEA testing as part of comprehensive tumour marker panels when your doctor is investigating an unclear liver or biliary finding, providing additional diagnostic context alongside more liver-specific markers like AFP and PIVKA-II.
CA19.9
CA19-9 serves as an important tumour marker particularly relevant to pancreatic and biliary tract cancers, both conditions closely related to liver health given the shared drainage system between the liver, gallbladder, and pancreas through the biliary tract.
This marker proves especially valuable for monitoring patients already diagnosed with pancreatic or biliary cancer, tracking treatment response and watching for recurrence, since these cancers often present without early symptoms, making any available monitoring tool genuinely valuable once a diagnosis has been established.
At Altus Lab, we recommend CA19-9 testing for patients with diagnosed pancreatic or biliary tract conditions requiring monitoring, and as supporting evidence alongside imaging when these cancers are clinically suspected but not yet confirmed through other diagnostic methods.
TTGA
Tissue Transglutaminase Antibody testing, while primarily associated with celiac disease screening, occasionally becomes relevant in liver investigation too, since celiac disease can sometimes present with unexplained elevated liver enzymes even without prominent digestive symptoms, an association not every patient or doctor initially considers.
This connection matters because celiac-related liver enzyme elevation typically resolves once a strict gluten-free diet is properly followed, making this an important, genuinely treatable consideration whenever standard liver disease investigation doesn’t identify a clear explanation for persistently abnormal results.
At Altus Lab, we recommend TTGA testing as part of a broader workup for unexplained elevated liver enzymes when more common causes have been reasonably ruled out, since identifying underlying celiac disease can resolve liver abnormalities without requiring liver-specific treatment at all.
IGG4
IgG4 testing measures a specific antibody subclass associated with IgG4-related disease, a condition that can affect the liver and pancreas directly, sometimes causing a distinctive form of pancreatitis or bile duct inflammation that can actually mimic pancreatic cancer on imaging studies.
This distinction carries real clinical importance, since IgG4-related disease responds well to steroid treatment, while mistaking it for cancer could lead to unnecessary, more invasive interventions. Recognising this condition through appropriate testing helps avoid this potentially significant diagnostic error.
At Altus Lab, we recommend IgG4 testing when imaging findings suggestive of pancreatic or biliary cancer don’t entirely fit the typical pattern, or when other inflammatory features are present, since correctly identifying this treatable, autoimmune-related condition can dramatically change the management approach.
Amylase & Lipase
Amylase and Lipase, two enzymes released by the pancreas, together form the primary blood test doctors rely on when diagnosing acute pancreatitis, a genuinely painful and potentially serious condition requiring prompt recognition, particularly relevant given how closely pancreatic and liver health interconnect.
Lipase generally offers better accuracy than amylase alone, remaining elevated for a longer window after an acute episode begins. Testing both together gives doctors the most complete picture, particularly important in emergency settings where rapid, accurate diagnosis directly affects treatment decisions.
At Altus Lab, we prioritise rapid processing for this panel, since acute pancreatitis often requires urgent treatment decisions, and confirming or ruling out this diagnosis quickly helps doctors determine the appropriate level of care needed without unnecessary delay.
Galactomannan GMI & B-D-Glucan (BDG)
Galactomannan and Beta-D-Glucan are specialised blood tests used to detect invasive fungal infections, particularly relevant for patients with compromised immune systems, including those with advanced liver disease, who face elevated risk for serious fungal infections that require rapid diagnosis and treatment.
These tests detect specific components of fungal cell walls circulating in the blood, offering earlier detection than traditional culture-based methods, which can take considerably longer to grow and identify fungal organisms, a delay that can genuinely matter for critically ill patients.
At Altus Lab, we recommend these tests for immunocompromised patients, including those with advanced liver disease or those on immunosuppressive treatment, presenting with unexplained fever or signs of serious infection, since early fungal infection detection significantly improves treatment outcomes in vulnerable patients.
Chromogranin-A Plasma
Chromogranin-A serves as a general marker for neuroendocrine tumours, a distinct category of tumours that can occasionally arise within or near the liver and pancreas, presenting differently from more common cancer types and sometimes producing hormones that cause their own distinct symptoms.
This test becomes relevant when a patient presents with symptoms suggestive of a neuroendocrine tumour, or when imaging identifies a mass with characteristics suggesting this less common tumour type, since Chromogranin-A elevation provides supporting biochemical evidence alongside imaging and, ultimately, tissue diagnosis.
At Altus Lab, we recommend Chromogranin-A testing when your specialist is specifically investigating a possible neuroendocrine tumour, providing valuable supporting evidence for this less common but clinically important category of tumours that require distinct diagnostic and treatment approaches.
How to Book Specialised Liver & Pancreatic Testing at Altus Lab
Several tests in this category, particularly amylase, lipase, and the fungal infection markers, are genuinely time-sensitive. Call or WhatsApp our team, share your prescription, and we will confirm which tests you need and prioritise urgent cases accordingly.
📞 Call: 0172-5017001 / 0172-5017002
💬 WhatsApp: +91-62842-14977
📍 SCO 35, Sector 16-D, Chandigarh
🕐 Open 7 Days: 7:30 AM – 9:30 PM
Home sample collection is available across Chandigarh, Mohali, and Panchkula.
Frequently Asked Questions
1. Can I have both viral hepatitis and autoimmune hepatitis at the same time?
While uncommon, it’s possible to have overlapping conditions. This is exactly why comprehensive testing, rather than assuming one cause, matters when investigating unexplained liver enzyme elevation.
2. Why would I need both AFP and PIVKA-II testing?
These markers work through different biological mechanisms, and combining them improves overall detection sensitivity for liver cancer surveillance compared to relying on either marker alone.
3. Is a positive AMA test always Primary Biliary Cholangitis?
While highly specific, your doctor will interpret AMA results alongside clinical symptoms and other liver tests, since diagnosis considers your complete clinical picture rather than one test result alone.
4. How urgent is Amylase and Lipase testing?
This test is genuinely urgent when acute pancreatitis is suspected, since prompt diagnosis directly influences treatment decisions and the appropriate level of medical care needed.
5. Who typically needs Galactomannan and BDG fungal marker testing?
These tests are primarily relevant for immunocompromised patients with signs of serious infection, not for routine or general health screening purposes.
6. Can IgG4-related disease really be mistaken for pancreatic cancer?
Yes, on imaging alone, these conditions can appear similar, which is why IgG4 testing provides valuable additional information to avoid unnecessary invasive procedures.
7. Does celiac disease testing make sense if I have no digestive symptoms?
Yes, in certain cases. Celiac disease can occasionally present primarily through unexplained liver enzyme elevation, even without prominent digestive symptoms, in some patients.
8. Who supervises these specialised tests at Altus Lab?
All autoimmune liver, tumour marker, and specialised panels are supervised by Dr. Alok Gupta, MD Pathology, Ex-PGIMER Chandigarh, ensuring accurate, clinically reviewed reporting.